Cytotoxicity of cisplatin and carboplatin used alone and in combination with the other anticancer drugs in the mouse embryo C3H10T1/2 cell line.
Cytotoxicity of cisplatin and carboplatin was compared using each drug alone and in combination with either 5-fluorouracil (5-FU) or methotrexate (MTX) and with 5-FU, vincristine (VCR) and bleomycin (BLM) together in the mouse embryo fibroblast line C3H10T1/2. The survival curves, drawn on the basis of the colony-forming ability of cells, indicated that carboplatin was about 25 times less effective in cell killing compared to cisplatin. Dose-response curves obtained with different concentrations of cisplatin combined with 5-FU or MTX showed a dose modification factor (DMF) of 1.8. A DMF of 5.7 was obtained when cisplatin was combined with 5-FU + VCR + BLM. A combination of carboplatin with 5-FU and MTX resulted in DMFs of 3.4 and 2.4, respectively, while a DMF of 4.8 was obtained by combining the platinum analogue with 5-FU + VCR + BLM. Initial shoulders in the cell survival curves resulting from treatments with cisplatin, carboplatin and 5-FU used as single agents disappeared after combined drug treatments. While the data generally indicated a higher cytotoxic effectiveness of combined drug treatments, there was no great difference between the DMFs for cisplatin and carboplatin when used in different combination protocols. These results may reflect the functional similarity of the two platinum compounds and suggest that the replacement of one with the other may not significantly alter the cytotoxic effectiveness in combined treatments.